Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2023 | Phase I trial of INA03 in patients with R/R acute leukemia: preliminary results

Sylvain Garciaz • 10 Jun 2023

EHA 2023

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Antibodies INA03

INA03

Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, briefly discusses the preliminary results from a Phase I trial evaluating the safety and efficacy of INA03, an anti-CD71 antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute leukemias (AL; NCT03957915). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Challenges with immunotherapy in AML: target antigen selection, T-cell exhaustion and more

Sylvain Garciaz • 10 Jun 2023

Single-center study evaluating the outcomes of patients with AML who relapsed after alloSCT

Sylvain Garciaz • 21 Mar 2023

The efficacy of ven-aza salvage therapy compared to azacitidine monotherapy in R/R AML

Sylvain Garciaz • 21 Mar 2023

Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax

Sylvain Garciaz • 21 Mar 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024